Overview

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

Status:
RECRUITING

Trial end date:
2031-06-01

Target enrollment:

Participant gender:

Summary

This study is to evaluate the effectiveness of treatment for esophagogastric junction carcinoma, total neoadjuvant therapy (TNT) including pembrolizumab and FLOT is conducted, aiming to choose between surgery or organ preservation treatment strategies.

Phase:

PHASE2

Details

Lead Sponsor:

National Cancer Center Hospital East

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

Docetaxel
Fluorouracil
Leucovorin
Oxaliplatin
pembrolizumab
Radiotherapy